NHS Wegovy Eligibility Calculator
Check whether you may fit the main NICE guidance points for NHS Wegovy access in England. This tool is for general guidance only. Final decisions depend on clinician assessment, referral criteria, and local specialist service availability.
What this checker looks at
The result is built around the main NICE structure: adult status, BMI range, lower thresholds for some ethnic backgrounds, at least one weight-related comorbidity, and access through a specialist weight-management pathway.
1. Are you 18 or over?
2. What is your current BMI?
BMI = weight in kilograms ÷ height in metres squared.
3. What is your ethnic background?
4. Do you have at least one weight-related health condition?
5. Are you in, or likely to qualify for referral to, a specialist weight-management service?
This tool gives general guidance only. It does not confirm NHS access, does not replace medical advice, and cannot account for local pathway differences or clinician judgement.
NHS Wegovy cost vs private treatment
NHS access can be far lower cost where treatment is approved, but Wegovy is recommended within specialist weight-management services and access is not universal. Private treatment is usually easier to access, but costs are much higher and vary by provider.
NHS prescription charge in England
- Based on £9.90 per item in England.
- Actual access still depends on specialist-service referral and approval.
- Exemptions and prepayment certificates can change what you pay.
Private treatment costs
- Access can be faster than NHS specialist pathways.
- Monthly costs are usually far higher than NHS prescription charges.
- Provider structure and support levels differ significantly.
How NHS Wegovy access usually works
Specialist service pathway
Semaglutide is recommended within a specialist weight-management service with multidisciplinary support, not as a simple open-access prescription route.
Diet and activity support
The NICE recommendation is for use alongside a reduced-calorie diet and increased physical activity, not as a stand-alone intervention.
6-month review point
Clinicians should consider stopping treatment if less than 5% of initial body weight has been lost after 6 months.
Complete NHS Wegovy criteria summary
This tool uses a plain-English summary of the main NICE recommendation points. Local NHS pathways may still add extra steps or service-specific restrictions.
Adult, at least one weight-related comorbidity, BMI 35 or above, and access through a specialist weight-management service.
Adult, at least one weight-related comorbidity, BMI 30 to 34.9, and meets referral criteria for specialist weight-management services.
NICE usually reduces BMI thresholds by 2.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean family backgrounds.
Frequently asked questions
Is Wegovy routinely available from the NHS?
Not as a simple general-access prescription. The NICE recommendation is within specialist weight-management services, and local availability can differ.
Why does this tool ask about comorbidities?
The NICE recommendation includes at least one weight-related comorbidity as part of the main eligibility structure for adult weight-management use.
What if I meet the BMI threshold but do not know my referral status?
That usually becomes a GP or specialist-service question. This tool marks those cases more cautiously because pathway access matters, not just BMI alone.
Can I still use private treatment if NHS access looks unlikely?
Yes. Many people compare regulated private providers when NHS access is unavailable, uncertain, or delayed. Private treatment should still involve appropriate clinical review.
How this tool works
The result is built from the public NICE recommendation structure for adult semaglutide weight-management use. It does not store your answers, does not send health details into analytics, and does not replace medical advice.
- Uses adult-only logic.
- Applies lower BMI thresholds for relevant ethnic backgrounds.
- Requires at least one weight-related comorbidity for likely eligibility.
- Includes specialist-service pathway status as part of the result.